Literature DB >> 17026558

Cytomegalovirus colitis complicating inflammatory bowel disease.

Ahmed Kandiel1, Bret Lashner.   

Abstract

When patients with inflammatory bowel disease (IBD) are admitted to the hospital with a flare of acute severe colitis, the possibility of a concurrent cytomegalovirus (CMV) infection causing or worsening the colitis is often considered. IBD patients are usually immunosuppressed, and therefore presumably at increased risk for active CMV infection and disease. Multiple techniques are used to diagnose CMV infection, including endoscopy, histology, serology, viral culture, CMV antigen testing, and CMV DNA testing. Immunohistochemistry (IHC) performed on colon biopsy specimens with monoclonal antibodies directed against CMV immediate early antigen is considered by most to be the current gold standard for diagnosis. The prevalence of CMV infection in acute severe colitis appears to be 21-34%, and the prevalence of CMV infection in the steroid refractory subgroup of these patients is 33-36%. After antiviral therapy, colitis remission rates in IBD patients with CMV infection range from 67% to 100%, though CMV histological infection or the presence of circulating virus alone is not always associated with steroid resistance, and may not require antiviral therapy.

Entities:  

Mesh:

Year:  2006        PMID: 17026558     DOI: 10.1111/j.1572-0241.2006.00869.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  81 in total

1.  Cytomegalovirus complicating inflammatory bowel disease: a 10-year experience in a community-based, university-affiliated hospital.

Authors:  Raed Al-Zafiri; Adrian Gologan; Polymnia Galiatsatos; Andrew Szilagyi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-04

2.  Cytomegalovirus in inflammatory bowel disease: A systematic review.

Authors:  Tessa E H Römkens; Geert J Bulte; Loes H C Nissen; Joost P H Drenth
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

3.  Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomes.

Authors:  Jeffrey D McCurdy; Edward V Loftus; William J Tremaine; Thomas C Smyrk; David H Bruining; Darrell S Pardi; Laura E Raffals; John B Kisiel; Nayantara Coelho-Prabhu; Sunanda V Kane; William A Faubion; Konstantinos A Papadakis
Journal:  Inflamm Bowel Dis       Date:  2013-10       Impact factor: 5.325

4.  Cytomegalovirus Reactivation in Ulcerative Colitis Patients.

Authors:  Minh Nguyen; Kara Bradford; Xiaolan Zhang; David Q Shih
Journal:  Ulcers       Date:  2011-01-01

5.  Hospital-Acquired Conditions Are Associated with Worse Outcomes in Crohn's Disease-Related Hospitalizations.

Authors:  Kenneth Obi; Alice Hinton; Lindsay Sobotka; Edward Levine; Darwin Conwell; Cheng Zhang
Journal:  Dig Dis Sci       Date:  2017-04-11       Impact factor: 3.199

6.  Cytomegalovirus Infection Exacerbates Experimental Colitis by Promoting IL-23 Production.

Authors:  Lingling Xuan; Lulu Ren; Feifei Han; Lili Gong; Zirui Wan; Song Yang; He Liu; Yali Lv; Lihong Liu
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

7.  Assessment of Disease Severity and Role of Cytomegalo Virus Infection in Patients with Ulcerative Colitis.

Authors:  Nobin Babu Kalappurayil; Jino Thomas; Baburajan Mankuni; Varghese Thomas
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease.

Authors:  Elena Garrido; Elisa Carrera; Rebeca Manzano; Antonio Lopez-Sanroman
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

9.  Murine norovirus: an intercurrent variable in a mouse model of bacteria-induced inflammatory bowel disease.

Authors:  Karen Chase Lencioni; Audrey Seamons; Piper M Treuting; Lillian Maggio-Price; Thea Brabb
Journal:  Comp Med       Date:  2008-12       Impact factor: 0.982

10.  Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease.

Authors:  Rachele Ciccocioppo; Francesca Racca; Luigia Scudeller; Antonio Piralla; Pietro Formagnana; Lodovica Pozzi; Elena Betti; Alessandro Vanoli; Roberta Riboni; Peter Kruzliak; Fausto Baldanti; Gino Roberto Corazza
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.